Literature DB >> 17482563

Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells.

Shinichi Tamura1, Hajime Hosoi, Yasumichi Kuwahara, Ken Kikuchi, Osamu Otabe, Moriatsu Izumi, Kunihiko Tsuchiya, Tomoko Iehara, Takahiro Gotoh, Tohru Sugimoto.   

Abstract

We aimed to examine the expression of EGFR in neuroblastoma tissues and to investigate the antitumor activity of a selective EGFR-tyrosine kinase inhibitor, gefitinib, on neuroblastoma. The expression of EGFR was detected in each of two tumor tissues by immunohistochemistry and eight of 10 cell lines by Western blotting. Gefitinib inhibited EGFR-phosphorylation and in vitro cell growth (IC(50): approximately 1.2 microM), and a high concentration of gefitinib (20-30 microM) induced apoptosis in vitro. This is the first report that EGFR protein is expressed on the cell surface in neuroblastoma tissues and in cell lines. We also demonstrated an EGFR inhibitor induced apoptosis on neuroblastoma cells. Our results suggest the feasibility of targeting EGFR as a novel strategy against neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482563     DOI: 10.1016/j.bbrc.2007.04.124

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Authors:  Abhik Bandyopadhyay; Edward Favours; Doris A Phelps; Vanessa Del Pozo; Samson Ghilu; Dias Kurmashev; Joel Michalek; Aron Trevino; Denis Guttridge; Cheryl London; Kenji Hirotani; Ling Zhang; Raushan T Kurmasheva; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2017-10-28       Impact factor: 3.167

Review 2.  Cell survival signaling in neuroblastoma.

Authors:  Michael L Megison; Lauren A Gillory; Elizabeth A Beierle
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

3.  Expression and significance of HER family receptors in neuroblastic tumors.

Authors:  Ewa Izycka-Swieszewska; Agnieszka Wozniak; Elzbieta Drozynska; Jacek Kot; Wieslawa Grajkowska; Teresa Klepacka; Danuta Perek; Sylwia Koltan; Ewa Bien; Janusz Limon
Journal:  Clin Exp Metastasis       Date:  2011-01-04       Impact factor: 5.150

4.  Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation.

Authors:  Cheng-Yi Chang; Chiung-Chyi Shen; Hong-Lin Su; Chun-Jung Chen
Journal:  J Neurooncol       Date:  2011-07-09       Impact factor: 4.130

5.  Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.

Authors:  Kristen N Richards; Patrick A Zweidler-McKay; Nadine Van Roy; Frank Speleman; Jesus Trevino; Peter E Zage; Dennis P M Hughes
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

6.  A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Authors:  Wayne L Furman; Lisa M McGregor; M Beth McCarville; Mihaela Onciu; Andrew M Davidoff; Sandy Kovach; Dana Hawkins; Valerie McPherson; Peter J Houghton; Catherine A Billups; Jianrong Wu; Clinton F Stewart; Victor M Santana
Journal:  Invest New Drugs       Date:  2011-07-28       Impact factor: 3.850

7.  Sensitivity of malignant rhabdoid tumor cell lines to PD 0332991 is inversely correlated with p16 expression.

Authors:  Yoshiki Katsumi; Tomoko Iehara; Mitsuru Miyachi; Shigeki Yagyu; Satoko Tsubai-Shimizu; Ken Kikuchi; Shinichi Tamura; Yasumichi Kuwahara; Kunihiko Tsuchiya; Hiroshi Kuroda; Tohru Sugimoto; Peter J Houghton; Hajime Hosoi
Journal:  Biochem Biophys Res Commun       Date:  2011-08-17       Impact factor: 3.575

8.  Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.

Authors:  Angela L Gaviglio; Erik H Knelson; Gerard C Blobe
Journal:  FASEB J       Date:  2017-02-07       Impact factor: 5.191

9.  Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.

Authors:  Daniela Meco; Tiziana Servidei; Anna Riccardi; Cristiano Ferlini; Gabriella Cusano; Gian Franco Zannoni; Felice Giangaspero; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2008-11-25       Impact factor: 12.300

10.  Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.

Authors:  Richard Gorlick; E Anders Kolb; Peter J Houghton; Christopher L Morton; Doris Phelps; Paula Schaiquevich; Clinton Stewart; Stephen T Keir; Richard Lock; Hernan Carol; C Patrick Reynolds; John M Maris; Jianrong Wu; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.